Aerie Pharmaceuticals, Inc. Names Vicente Anido, Jr. as Chairman of the Board, and David Epstein as Chairman of Aerie’s Scientific Advisory Board
4/4/2013 6:28:06 AM
More...
|
Aerie Pharmaceuticals, Inc. to Present at 31st Annual J.P. Morgan Healthcare Conference
1/3/2013 6:51:34 AM
More...
|
Aerie Pharmaceuticals, Inc. Looks to Raise $15 Million
12/20/2012 8:10:18 AM
More...
|
BioLight Life Sciences Investments Ltd and Aerie Pharmaceuticals, Inc. Affiliates Announce a Collaboration for Continued Development of a Controlled-Release Ocular Implant for the Delivery of Ophthalmic Medications
11/7/2012 9:39:01 AM
More...
|
Aerie Pharmaceuticals, Inc. Gets Good News on Glaucoma Treatment
11/2/2012 6:27:58 AM
More...
|
Aerie Pharmaceuticals, Inc. Announces Positive Phase 2a Clinical Results for a Fixed Combination of its Rho Kinase Inhibitor, AR-12286, With Travoprost for the Treatment of Glaucoma
11/1/2012 8:53:09 AM
More...
|
Aerie Pharmaceuticals, Inc. Appoints Richard J. Rubino as Chief Financial Officer
10/18/2012 9:38:09 AM
More...
|
Aerie Pharmaceuticals, Inc. Completes $30 Million Series B Financing to Fund Further Development of Innovative Glaucoma Product Portfolio
3/7/2011 6:28:40 AM
More...
|
Aerie Pharmaceuticals, Inc.'s ROCK Inhibitor, AR-12286, Demonstrates Positive Results in Glaucoma Patients in a Phase 2a Study
10/22/2009 9:36:58 AM
More...
|